A T-cell protein that sparks joint inflammation in rheumatoid arthritis
CD8 T cell derived Granzyme K activates complement that drives synovial fibroblast inflammation
Researchers are looking at whether a protein made by a type of T cell (granzyme K) turns on complement proteins that make the joint lining cells inflamed in people with rheumatoid arthritis.
Quick facts
| Grant type | R01 grant |
|---|---|
| Study type | NIH-funded research |
| Funding institution | Brigham and Women's Hospital NIH-funded |
| Lab location | 1 site (Boston, United States) |
| Project ID | NIH-11173621 on NIH RePORTER |
What this research studies
This work looks at immune cells taken from inflamed joints and blood of people with rheumatoid arthritis to see how CD8 T cells release granzyme K and how that protein interacts with complement proteins made by joint-lining fibroblasts. The team measures whether granzyme K can cut complement components to create active fragments (like C3a/C3b) and whether those fragments make fibroblasts and mast cells more inflammatory. They use human synovial tissue and cells and build on mouse data showing complement can prime fibroblasts, aiming to connect the cell-level events to human disease. The goal is to map the pathway by which CD8 T cell signals could drive persistent joint inflammation.
Who could benefit from this research
Good fit: People with rheumatoid arthritis, especially those with active joint inflammation who can provide blood or synovial tissue samples, would be most relevant to this work.
Not a fit: People without rheumatoid arthritis or with noninflammatory joint conditions (for example plain osteoarthritis) are unlikely to benefit directly from this specific line of research.
Why it matters
Potential benefit: If confirmed, this could point to a new target to reduce harmful inflammation in rheumatoid arthritis and lead to new treatment strategies.
How similar studies have performed: Prior studies have shown complement can prime mouse synovial fibroblasts, but linking CD8 T cell–derived granzyme K to human complement activation and fibroblast inflammation is a relatively new finding under active study.
Where this research is happening
Boston, United States
- Brigham and Women's Hospital — Boston, United States (Active)
Researchers
- Principal investigator: Brenner, Michael B. — Brigham and Women's Hospital
- Study coordinator: Brenner, Michael B.
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page below.